1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Prazepam Capsules

Trade Name: Prasepine
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Antidepressant/antianxiety.

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
<tr>
<td>Prazepam</td>
<td>2955-38-6</td>
<td>220-975-8</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Capsules
Signal Word: WARNING

Statement of Hazard:
Suspected of damaging fertility.
May cause central nervous system effects

Additional Hazard Information:
Short Term: Not acutely toxic (based on components).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, male reproductive system.

Known Clinical Effects:
Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremors, headache, and gastrointestinal disturbances. This material has been shown to be secreted in low concentrations in human breast milk. The following effects are based on a chemically-related material: symptoms of dependence/withdrawal, insomnia, amnesia, agitation, nightmares, hallucinations.

EU Indication of danger: Not classified
Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not determined

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE
Material Name: Prazepam Capsules
Revision date: 15-Dec-2006
Page 3 of 6
Version: 1.1

General Handling: Avoid generating airborne dust. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

Storage Conditions: Store at controlled room temperature. Protect from light.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate
ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals
Australia TWA = 10 mg/m³ TWA

Prazepam
Pfizer OEL TWA-8 Hr: 0.02 mg/m³

The exposure limit(s) listed for solid components are only relevant if dust may be generated.


Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Capsule
Molecular Formula: Mixture
Color: No data available.
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Light
Incompatible Materials: No data available

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Prazepam
Mouse Oral LD50 2.3 g/kg
Rat Oral LD50 >4 g/kg
Rat IP LD50 >2 g/kg
Material Name: Prazepam Capsules
Revision date: 15-Dec-2006

12. ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. Environmental properties have not been thoroughly investigated.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.
14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
WARNING
Suspected of damaging fertility.
May cause central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a very toxic materials

Lactose

Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS List: 200-559-2

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS List: 209-150-3

Prazepam

Drug Enforcement Administration: Schedule IV
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS List: 220-975-8

Additional Information: US DEA Schedule IV substance

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet